Trulicity is currently holding its own in sales despite competition. (Eli Lilly)
Trulicity Company: Eli Lilly 2019 sales: $4.13 billion Projected 2026 sales: $7.43 billion Projected CAGR: +9% Used for: glycemic control for Type 2 diabetes
Eli Lilly's GLP-1 diabetes fighter Trulicity has been locked in a battle for sales supremacy with Novo Nordisk's Ozempic and oral follow-up drug Rybelsus. But with a recent first-of-its-kind approval in tow, Trulicity could be well positioned to keep adding to its blockbuster sales in the coming years despite the pressure.
Trulicity snagged $4.13 billion in 2019 sales in its fifth year on the market. With a new cardiovascular risk reduction label expansion, the drug could be set to reach $7.43 billion in sales in 2026, Evaluate Pharma predicted.
That new CV approval could prove to be a gamechanger not only for Trulicity but also the rest of the GLP-1 class, including the fierce rivals from Novo.